The present status and the recent development of the treatment for inflammatory bowel diseases: Desirable effect of extracorporeal immunomodulation

Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis

Volumn 6, Issue 4, 2002, Pages 305-311

  Takazoe, Masakazu ^a   Tanaka, Torao ^a   Kondo, Kenji ^a   Ichimori, Toshiki ^a   Shinoda, Toshio ^b  

^a Department of Medicine   (Japan)

^b Social Insurance Chuo General Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOLOGICAL ADJUVANT;

ENTERITIS; HUMAN; IMMUNOLOGY; LEUKAPHERESIS; REVIEW;

ADJUVANTS, IMMUNOLOGIC; HUMANS; INFLAMMATORY BOWEL DISEASES; LEUKAPHERESIS;

EID: 0036677037     PISSN: 10916660     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1526-0968.2002.00445.x     Document Type: Review

References (32)

1. 1 Takazoe M. Therapy of Crohn's disease–anti‐TNF‐α antibody therapy. J Jpn Soc Intern Med 2001 ; 30: 146–54.
2. 2 Sands BE. Therapy of inflammatory bowel disease. Gastroenterology 2002 ; 118: 568–82.
3. 3 Taurog JD, Richardson JA, Croft JT, Simmons WA, Zhou M, Fernandez‐Sueiro JL, Balish E, Hammers RE. The germfree state prevents development of gut and joint inflammatory disease in HLA‐B27 transgenic rats. J Exp Med 1994 ; 180: 2359–64.
4. 4 Sadlac B, Merz H, Schorie H, Schimpi A, Feller AC, Horak I. Ulcerative colitis‐like disease in mice with a disrupted interleukin‐2 gene. Cell 1993 ; 75: 253–61.
5. 5 Plevy SE, Landers CJ, Prehn J, Carramanzana NM, Deem RL, Shealy D. A role for TNF‐alpha and mucosal T helper‐1 cytokines in the pathogenesis of Crohn's disease. J Immunol 1997 ; 159: 6276–82.
6. 6 Fuss IJ, Neutrath M, Boirivant M, Klein JS, De La Motte C, Strong SA, Fiocchi C, Strober W. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. J Immunol 1996 ; 157: 1261–70.
7. 7 Desreumax P, Brandt E, Gambiez L, Emilie D, Geboes K, Klein O, Ectors N, Cortot A, Capron M, Colombel JF. Distinct cytokine pattern in early and chronic ileal lesions of Crohn's disease. Gastroenterology 1997 ; 113: 118–26.
8. 8 Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration. Cell 1994 ; 76: 301–4.
9. 9 Picarella D, Hurlbut P, Rottman J, Shi X, Butcher E, Ringler DJ. Monoclonal antibodies specific for beta7 integrin and mucosal addresin cell adhesion molecule 1 (MadCAM‐1) reduce inflammation in the colon of scid mice reconstituted with CD45Rb high CD4+ T cells. J Immunol 1997 ; 158: 2099–106.
10. 10 Conner EM, Brands SJ, Davis JM, Kang DY, Grisham MB. Role of reactive metabolites of oxygen and nitrogen in inflammatory bowel disease. Inflamm Bowel Dis 1996 ; 2: 133–47.
11. 11 Malchow H, Ewe K, Brandes JW, Goebell H, Ehms H, Sommer H, Jesdinsky H. European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology 1984 ; 86: 249–66.
12. 12 Summers RW, Switz DM, Sessions JT Jr, Becktel JM, Best WR, Kern F Jr, Singleton JW. National cooperative Crohn's disease: results of drug treatment. Gastrenterology 1979 ; 77: 847.
13. 13 Lofberg R. New steroids for inflammatory bowel disease. Inflamm Bowel Dis 1995 ; 1: 135–41.
14. 14 Fegan BG, Fedorak RN, Irvine EJ, Wild G, Sutherland L, Steinhart AH, Greenberg GR, Koval J, Wong CJ, Hopkins M, Hanauer SB, McDonald J. A comparison of methotrexate with placebo for the maintenance of remission of Crohn's disease. N Engl J Med 2000 ; 342: 1627–32.
15. 15 Fernandez‐Benares F, Bertran X, Esteve‐Comas M, Cabre E, Menacho M, Humbert P, Planas R, Gassull MA. Azathioprine is useful in maintaining long‐term remission induced by intravenous cyclosporine in steroid refractory severe ulcerative colitis. Am J Gastroenterol 1996 ; 91: 2498–9.
16. 16 Siegel SA, Shealy DJ, Nakada MT, Le J, Woulfe DS, Probert L, Kollias G, Ghrayeb J, Vicek J, Daddona PE. The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo. Cytokine 1995 ; 7: 251–9.
17. 17 Sandborn WJ, Hanauer SB. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis 1999 ; 5: 119–33.
18. 18 Targan SR, Hanauer SB, Van Deventer SJH, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible T, Rutgeerts PJ. A short‐term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. N Engl J Med 1997 ; 337: 1029–35.
19. 19 Rutgeerts P. Infliximab is the drug we have been waiting for in Crohn's disease. Inflamm Bowel Dis 2000 ; 6: 132–6.
20. 20 Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, Van Hogezand RA, Podolsky DK, Sands BE, Braakaman T, DeWoody KL, Schaible TF, Van Denenter SJ. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999 ; 340: 1398–405.
21. 21 Bickston SJ, Lichtenstein GR, Arseneau KO, Cohen RB, Cominelli F. The relationship between infliximab treatment and lymphoma in Crohn's disease. Gastroenterology 1999 ; 117: 1433–7.
22. 22 Vermeire S, Monsuur F, Groenen P, Peeters M, Vlietinck R, Rutgeerts P. Response to anti‐TNFα treatment is associated with the TNFA‐308*1 allele (abstract). Gastroenterology 2000 ; 118: A654.
23. 23 Boirivant M, Marini M, Di Felice G, Pronio AM, Montesani C, Tersigni R, Stober W. Lamina propria T cells in Crohn's disease and other gastrointestinal inflammation show defective CD2 pathway‐induced apoptosis. Gastroenterology 1999 ; 116: 557–65.
24. 24 Ina K, Itoh J, Fukushima K, Kusugami K, Yamaguchi T, Kyokane K, Imada A, Binion DG, Musso A, West GA, Dobrea GM, McCormick TS, Lapetina EG, Levine AD, Ottaway CA, Fiocchi C. Resistance of Crohn's disease T cells to multiple apoptotic signals is associated with Bcl‐2/Bax mucosal imbalance. J Immunol 1999 ; 163: 1081–90.
25. 25 Atreya R, Mudter J, Finotto S, Müllberg J, Jostock T, Wirtz S, Schütz M, Bartsch B, Holtmann M, Becker C, Strand D, Czaja J, Schlaak FJ, Lehr HA, Autschbach F, Schürmann G, Nishimoto N, Yoshizaki K, Ito H, Kishimoto T, Galle PR, Rose‐John S, Neurath MF. Blockade of interleukin 6 trans signaling suppresses T‐cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn's disease and experimental colitis in vivo. Nature Med 2000 ; 6: 583–8.
26. 26 McDonald TT. Viral vectors expressing immunoregulatory cytokines to treat inflammatory bowel diseases. Gut 1998 ; 42: 460–1.
27. 27 Modigliani R, Mary JY, Simon JF, Cortot A, Soule JC, Gendre JP, Rene E. Clinical, biological, and endoscopic picture of attacks of Crohn's disease, evolution on prednisolone. Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives. Gastroenterology 1990 ; 98: 811–8.
28. 28 Sawada K, Ohnishi S, Fukui S, Yamada K, Yamamura M, Amano K, Amano K, Wada M, Tanida M, Satomi M, Shimoyama T. Leukocytapheresis therapy, performed with leukocyte removal filter, for inflammatory bowel disease. J Gastroenterol 1995 ; 30: 322–9.
29. 29 Kondo K, Shinoda T, Yoshimoto H, Takazoe M, Hamada T. Effective maintenance leukocytapheresis for patients with steroid dependent or resistant ulcerative colitis. Ther Apher 2001 ; 5: 462–5.
30. 30 Fukushima T, Sugita A, Koganei K, Shinozaki M. The incidence and outcome of pelvic sepsis following handsewn and stapled ileal pouch anal anastomosis. Surg Today 2000 ; 30: 223–7.
31. 31 Belliveau P, Trudel J, Vasilevsky CA. Ileoanal anastomosis with reservoirs: complication and long‐term results. Can J Surg 1999 ; 42: 345–52.
32. 32 Heuschen UA, Heuschen G, Herfarth C. Ileoanal pouch as rectal substitute. Chirurg 1999 ; 70: 530–42. DOI: 10.1007/s001040050684